wire - news in brief
« BACK
Health - Pharmacology - 16.10.2020
Pharmacology - Health - 16.10.2020
Health - Pharmacology - 13.10.2020
Health - Pharmacology - 09.10.2020
Pharmacology - Health - 05.10.2020
Pharmacology - Health - 01.10.2020
Pharmacology - Health - 23.09.2020
Health - Pharmacology - 21.09.2020
Pharmacology - Health - 19.09.2020
Pharmacology - Health - 19.09.2020
Health - Pharmacology - 18.09.2020
Health - Pharmacology - 16.09.2020 
New Findings Recommend Patients with a Low HIV Viral Load Switch to Second-line Antiretroviral Therapy
HIV continues to be a major global health issue, having claimed almost 33 million lives.
Pharmacology - Health - 16.09.2020
Health - Pharmacology - 15.09.2020
Pharmacology - Health - 14.09.2020
Pharmacology - Health - 14.09.2020
Pharmacology - Health - 11.09.2020
Pharmacology - Health - 11.09.2020
Pharmacology - Health - 08.09.2020
Health - Pharmacology - 08.09.2020 
"These results are crucial for the future corona vaccination strategy"
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.
Pharmacology - Health - 07.09.2020
Pharmacology - Health - 02.09.2020
Health - Pharmacology - 01.09.2020
Health - Pharmacology - 01.09.2020
Pharmacology - Health - 30.08.2020
Pharmacology - Health - 29.08.2020
Pharmacology - Health - 26.08.2020
Pharmacology - Health - 22.08.2020
Pharmacology - Health - 20.08.2020
Pharmacology - Health - 17.08.2020
Pharmacology - Health - 11.08.2020
Pharmacology - Health - 10.08.2020
Pharmacology - Health - 07.08.2020
Pharmacology - Health - 06.08.2020
Pharmacology - Health - 05.08.2020
Pharmacology - Health - 04.08.2020
Pharmacology - Health - 03.08.2020
Health - Pharmacology - 29.07.2020
Pharmacology - 27.07.2020
Pharmacology - Health - 27.07.2020
Pharmacology - Health - 24.07.2020
Pharmacology - Health - 23.07.2020
Pharmacology - Economics / Business - 21.07.2020
Health - Pharmacology - 16.07.2020
Health - Pharmacology - 15.07.2020 
Drones to Deliver Tuberculosis Drugs in Madagascar
The use of drones in global health settings has rapidly evolved in the past years. As drone technology continues to expand beyond the military and recreational sectors, it is foreseen that it will have a significant role to play in healthcare delivery.
Pharmacology - Health - 13.07.2020
Pharmacology - Health - 10.07.2020
Pharmacology - Health - 07.07.2020
Health - Pharmacology - 06.07.2020 
"We have the here and now. That’s all we really have."
Acceptance and Commitment Therapy (ACT) is still a relatively young approach from behavioral therapy, but has already proven itself in the treatment of a wide range of mental disorders.
Pharmacology - Health - 01.07.2020
Pharmacology
Results 1 - 50 of 1467.
Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection This new solution will run on all Roche cobas e immunochemistry analys
The Elecsys SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection This new solution will run on all Roche cobas e immunochemistry analys
New Phase III analysis demonstrates Novartis Beovu showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
In a post-hoc analysis of HAWK and HARRIER , fewer Beovu (brolucizumab ) patients had early persistent fluid (12 .5% vs.
In a post-hoc analysis of HAWK and HARRIER , fewer Beovu (brolucizumab ) patients had early persistent fluid (12 .5% vs.
Zolgensma data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement
Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10&
Nearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10&
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (I T) formulation in older patients with SMA to further support registration Basel, Septembe
Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (I T) formulation in older patients with SMA to further support registration Basel, Septembe
Novartis Kisqali receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale
Kisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score - confirming substantial benefit for premenopausal women with HR+/HER2- advanced bre
Kisqali is the only CDK4/6 inhibitor, in combination with endocrine therapy, to achieve a perfect 5 out of 5 score - confirming substantial benefit for premenopausal women with HR+/HER2- advanced bre
Patches to detect when a viral disease is about to get worse
Xsensio, an EPFL spin-off, has just been awarded CHF 1.8 million in EU funding to adapt its Lab-on-Skin(TM) sensing patches so that they can detect when a viral illness like the flu or COVID-19 is about to get worse.
Xsensio, an EPFL spin-off, has just been awarded CHF 1.8 million in EU funding to adapt its Lab-on-Skin(TM) sensing patches so that they can detect when a viral illness like the flu or COVID-19 is about to get worse.
HIV continues to be a major global health issue, having claimed almost 33 million lives.
Novartis Tafinlar + Mekinist demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma 1 Adjuvant treatment with
COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma 1 Adjuvant treatment with
European Medicines Agency (EMA) approves safety label update for Novartis Beovu
Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal vasculitis a
Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD The update includes the additional characterization of retinal vasculitis a
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to di
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to di
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.
Novartis post hoc analysis shows high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale
Novartis announces NEJM publication of pivotal study of Tabrecta(TM) in patients with METex14 metastatic non-small cell lung cancer
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar + Mekinist in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg
FDA approves Novartis Kesimpta (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple scleros
FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a person with NMOSD or a caregiver every four weeks First and o
FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis 1
Novartis announces Kymriah meets primary endpoint at interim analysis of pivotal study in follicular lymphoma
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously receive
Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously receive
Novartis Cosentyx receives EU approval for first-line systemic treatment in pediatric psoriasis
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
EU approval is based on two Phase III studies showing Cosentyx provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile 1 Modera
Novartis receives Piqray approval in Europe - the first and only targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation, underscoring Novartis commitment to reimagining cancer care Approval based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS (11.0 vs.
New Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu versus aflibercept
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,
A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept,
The use of drones in global health settings has rapidly evolved in the past years. As drone technology continues to expand beyond the military and recreational sectors, it is foreseen that it will have a significant role to play in healthcare delivery.
New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A
Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3 STASEY is the largest
Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from phase III HAVEN studies, with no new safety signals identified 1,2,3 STASEY is the largest
Acceptance and Commitment Therapy (ACT) is still a relatively young approach from behavioral therapy, but has already proven itself in the treatment of a wide range of mental disorders.
